| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 05/24/2006 | EP1658081A2 Immunosuppressive effects of pteridine derivatives |
| 05/24/2006 | EP1478613B1 Substituted 10-aryl-11h-benzo¬b|fluorenes for selective effects on estrogen receptors |
| 05/24/2006 | EP1474425B1 Deazapurines and uses thereof |
| 05/24/2006 | EP1427428B1 Apoptosis-mimicking natural vesicles and use thereof in medical treatment |
| 05/24/2006 | EP1389619B1 Pkb-3564 substance with neovascularization inhibitory activity |
| 05/24/2006 | EP1370526B1 Diamides which inhibit tryptase and factor xa activity |
| 05/24/2006 | EP1333841B1 M. tuberculosis chaperonin 10 and uses thereof |
| 05/24/2006 | EP1254904B1 Novel piperidine compounds and drugs containing the same |
| 05/24/2006 | EP1226129B1 Methods and compositions utilizing quinazolinones |
| 05/24/2006 | EP1196151B1 Transdermal therapeutic system for administering a calcium antagonist |
| 05/24/2006 | EP1121382B1 Interferon-beta fusion proteins and uses |
| 05/24/2006 | EP1115397B1 Compositions for mitigating the adverse effects of interleukin-2 |
| 05/24/2006 | EP1100492B1 INDOLE sPLA2 INHIBITORS |
| 05/24/2006 | EP1001974B1 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2006 | DE102004054847A1 Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament Substituted benzoylguanidines, processes for their preparation, their use as a medicament or diagnostic, and they drug-containing |
| 05/24/2006 | CN1777678A Method of treating ischemic disease |
| 05/24/2006 | CN1777676A Schizophrenia-related voltage-gated ion channel gene and protein |
| 05/24/2006 | CN1777608A Fused pyrimidine derivative |
| 05/24/2006 | CN1777606A 4-(4-trans-hydroxycyclohexyl)amino-2-phenyl-7h-pyrrolo [2, 3d]pyrimidine hydrogen mesylate and its polymorphic forms |
| 05/24/2006 | CN1777595A Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics |
| 05/24/2006 | CN1777429A Prostaglandin compositions and applications for the treatment of vasospasm |
| 05/24/2006 | CN1777420A Processed fat composition for preventing/ameliorating lifestyle-related diseases |
| 05/24/2006 | CN1777416A Lactate containing pharmaceutical composition and uses thereof |
| 05/24/2006 | CN1775801A Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction |
| 05/24/2006 | CN1775762A Liyustrazine acyl piperazine derivative, and its preparing method and medicinal composition and use |
| 05/24/2006 | CN1775285A Use of glucoprotein for pharmaceuticals |
| 05/24/2006 | CN1775253A Chinese hawthorn blood-pressure-reducing preparation, and new preparing method |
| 05/24/2006 | CN1775251A Method for preparing piles-treating Chinese modicine |
| 05/24/2006 | CN1775249A Camellia-flower total flavone medicinal preparation, its preparing method and use |
| 05/24/2006 | CN1775233A Red-rooted-salvia-root chuanxiong-rhizome azine injecta, its preparation method and use |
| 05/24/2006 | CN1775219A Medicinal formulation for preventing and treating ischemic vascular disease, and its preparing method and use |
| 05/24/2006 | CN1775209A Magnetic target slow-release catopril and its preparing method |
| 05/24/2006 | CN1775207A Esmolol formulation |
| 05/24/2006 | CN1257286C Targeted adenovirus vectors for delivery of heterologous genes |
| 05/24/2006 | CN1257259C Formulation for health-care red rice wine |
| 05/24/2006 | CN1257160C Aimoquinoline and aminopyridine derivatives and their use as adenosine A3 ligands |
| 05/24/2006 | CN1257158C N-aryl substituted-1H-pyrrole derivative possessing cardiovascular activity |
| 05/24/2006 | CN1256949C Notoginsen total saponin plastid and prepartion thereof |
| 05/24/2006 | CN1256944C Preparation method of captopril compounding chitosan slow release micro ball |
| 05/24/2006 | CN1256940C Compound Chinese medicine notoginseng dripping pills and its preparation process |
| 05/24/2006 | CN1256939C Coenzyme Q10 containing microemulsion preconcentrates and microemulsions |
| 05/23/2006 | US7049411 Human anti-factor IX/IXa antibodies |
| 05/23/2006 | US7049403 Insulin/IGF/relaxin family polypeptides and DNAS thereof |
| 05/23/2006 | US7049402 Tumor necrosis factor receptor-5 |
| 05/23/2006 | US7049345 Fat-binding polymers |
| 05/23/2006 | US7049336 Method for diagnosing neuronal diseases and for treating primary hemostasis deficiency |
| 05/23/2006 | US7049329 Phenylalkylene-substituted or allyloxyphenylmethyl-substituted, e.g., N-(p-allyloxybenzyl-N-(2-methoxyethyl)-N-(3-phenylallyl)amine; endocannabinoid agonists |
| 05/23/2006 | US7049328 Use for deferiprone |
| 05/23/2006 | US7049326 Altering a drug's distribution, metabolism and elimination properties, especially by modifying with aralkyl ester moieties to increase rate of metabolism to inactive and nontoxic metabolites when exposure is halted; surgery, riots |
| 05/23/2006 | US7049322 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor |
| 05/23/2006 | US7049321 Methods and pharmaceutical compositions for treatment of central and peripheral nervous system disorders and compounds useful therefor |
| 05/23/2006 | US7049320 Drugs for treating physiological disorder, respiratory disorders, inflammatory disease, skin disorder, and antidepressants, treating bipolar disorder, drug abuse, drug dependence, gastrointestinal disorder, atherosclerosis |
| 05/23/2006 | US7049312 2H-1,4-benzothiazin-3(4H)-one derivative as anticarcinogenic and antiproliferative agent; inhibitors of serine/threonine and tyrosine kinase activity |
| 05/23/2006 | US7049306 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4. |
| 05/23/2006 | US7049124 Hyaluronidase from the Hirudinaria manillensis isolation, purification and recombinant method of production |
| 05/23/2006 | US7049119 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 05/23/2006 | US7049079 Coupling factor 6 inhibitor and potentiator and use thereof |
| 05/23/2006 | US7049066 Diagnosis and treatment of myocardial failure |
| 05/23/2006 | US7048954 Method for preparing an extract of ginkgo biloba leaves highly enriched in active principles |
| 05/23/2006 | US7048927 treating a cardiovascular disease, especially preventing restenosis in a blood vessel which may occur following a cardiovascular procedure, |
| 05/23/2006 | CA2339630C Carboline derivatives as cgmp phosphodiesterase inhibitors |
| 05/23/2006 | CA2312729C Use of 9-deoxy-2', 9-.alpha.-methano-3- oxa-4,5,6- trinor-3, 7-(1',3'-interphenylene) -13,14-dihydro- prostaglandin f1 to treat peripheral vascular disease |
| 05/23/2006 | CA2301189C Non-steroidal ligands for the estrogen receptor |
| 05/23/2006 | CA2263921C Oral delayed immediate release formulation and method of preparation therefor |
| 05/23/2006 | CA2232141C Substituted tetracyclic tetrahydrofuran derivatives |
| 05/23/2006 | CA2188841C Use of 2-amino-4-(4-fluorobenzylamino)-1-ethoxy-carbonylaminobenzene for the prophylaxis and treatment of the sequelae of acute and chronic reduced cerebral blood supply and neurodegenerative disorders |
| 05/23/2006 | CA2173747C Calcium receptor-active arylalkyl amines |
| 05/18/2006 | WO2006053161A1 Use ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure |
| 05/18/2006 | WO2006053037A2 A new dosing regimen for ion channel modulating compounds for treating acute atrial fibrillation in a human |
| 05/18/2006 | WO2006052454A1 Propranolol formulations |
| 05/18/2006 | WO2006052405A1 Propranolol formulations |
| 05/18/2006 | WO2006052026A1 Acid salt of benzimidazole derivative and crystal thereof |
| 05/18/2006 | WO2006051987A1 Novel drug for inhibiting estrogen-dependent diseases, prostaglandin d (pgd)-dependent gynecological diseases, immunological diseases, cancer and angiogenesis |
| 05/18/2006 | WO2006051826A1 Nitrogenous heterocyclic compound and pharmaceutical use thereof |
| 05/18/2006 | WO2006051757A1 Remedy or preventive for ischemic cardiac disease or ischemic cardiac myopathy |
| 05/18/2006 | WO2006051648A1 Remedy for angiospasm accompanying subarachnoid hemorrhage contianing thrombin receptor antagonist as the active ingredient |
| 05/18/2006 | WO2006051502A2 Sulfamides as endothelin receptor antagonists for the treatment of cardiovascular diseases |
| 05/18/2006 | WO2006051410A1 Azabenzoxazoles for the treatment of cns disorders |
| 05/18/2006 | WO2006051314A2 Guanidine derivatives as inhibitors of ddah |
| 05/18/2006 | WO2006050921A2 Preparation of telmisartan salts with improved solubility |
| 05/18/2006 | WO2006050830A1 Substituted benzoylguanidines method for production and use thereof as medicament or diagnostic and medicament comprising the same |
| 05/18/2006 | WO2006050819A1 Pharmaceutical preparation for the treatment of friedreich’s ataxia |
| 05/18/2006 | WO2006050598A1 Dual antiplatelet/anticoagulant pyridoxine analogs |
| 05/18/2006 | WO2006050591A2 Process for the synthesis of poly (vinyl alcohol) and/or poly (vinyl acetate) with spherical morphology and shell- and-nucleus structure and its use in vascular embolization |
| 05/18/2006 | WO2006050585A2 Modulation of nitric oxide synthases by betaines |
| 05/18/2006 | WO2005120540A3 Interferon alpha or beta for treatment of cardiomyopathy and endothelial dysfunction |
| 05/18/2006 | WO2005085424A3 Endothelial progenitor cells and methods of use thereof |
| 05/18/2006 | WO2005058280A3 Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure |
| 05/18/2006 | US20060106232 atorvastatin hemi-calcium Form X and solvates of given powder X-ray diffraction pattern; small particle size distribution; dosage forms |
| 05/18/2006 | US20060106231 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| 05/18/2006 | US20060106222 Aminoadamantane derivatives as therapeutic agents |
| 05/18/2006 | US20060106220 Compositions and therapeutic methods involving isoflavones and analogues thereof |
| 05/18/2006 | US20060106111 Phenylnaphthalene compounds |
| 05/18/2006 | US20060106108 Method for scavenging radicals with urocanic acid, derivatives and analogues |
| 05/18/2006 | US20060106082 N-[4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenylsulfonyl]-4-nitrooxybutanamide, used for the treatment of inflammatory, cardiovascular, gastrointestinal, respiratory and nervous system disorders, as analgesics, antipyretics and antocoagulants or for organ and tissue preservation |
| 05/18/2006 | US20060106074 Er-b-selective ligands |
| 05/18/2006 | US20060106069 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1-(toluene-4-sulfonyl)-1H-pyrrole-2-carboxylic acid methyl ester; mitogen-activated protein kinase inhibitor; antiproliferative, anticarcinogenic agent; study of intracellular signal transduction pathways; evaluation of new kinase inhibitors |
| 05/18/2006 | US20060106059 Melanocortin receptor ligands |
| 05/18/2006 | US20060106057 Stabilization of quinapril using magnesium oxide |
| 05/18/2006 | US20060106050 Thrombin receptor antagonists |